Key points from article :
RepliCel Life Sciences has retained leading clinical research organization, Accerise Inc.
Accerise to lead the clinical studies of RepliCel's skin rejuvenation and tendon regeneration cell therapy products in Japan.
Will support in the design of the clinical study protocols, procuring the collaboration of all clinical sites, obtaining all necessary approvals from IRBs, oversight committees, and the Ministry of Health, Labour and Welfare (MHLW) including certification, training, and the establishment of the necessary systems to ensure high-quality GCP-compliant data.
RepliCel is preparing for the clinical testing and commercialization of three technologies in Japan.
These include two cell therapies and a next-generation dermal injector for aesthetic treatments.
Both cell therapies have been the subject of successful phase 1 studies in Germany and Canada.
Upon successfully meeting its endpoints, could lead to a commercial launch of the products in Japan.
